Published in J Pharm (Cairo) on September 12, 2013
In vivo protein transduction: delivery of a biologically active protein into the mouse. Science (1999) 10.70
Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol (2011) 9.68
Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci U S A (1994) 6.61
Endothelial cell-to-cell junctions: molecular organization and role in vascular homeostasis. Physiol Rev (2004) 4.12
Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience (2004) 2.86
Molecular physiology and pathophysiology of tight junctions in the blood-brain barrier. Trends Neurosci (2001) 2.68
RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system. Mol Ther (2006) 2.59
Nasal drug delivery--possibilities, problems and solutions. J Control Release (2003) 2.53
Blood-brain barrier drug targeting: the future of brain drug development. Mol Interv (2003) 2.06
Efficient and targeted delivery of siRNA in vivo. FEBS J (2010) 1.84
Different roles of the IGF-I Ec peptide (MGF) and mature IGF-I in myoblast proliferation and differentiation. FEBS Lett (2002) 1.82
Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci (2008) 1.81
Intrathecal chemotherapy: brain tissue profiles after ventriculocisternal perfusion. J Pharmacol Exp Ther (1975) 1.63
Minireview: Mechano-growth factor: a putative product of IGF-I gene expression involved in tissue repair and regeneration. Endocrinology (2010) 1.38
Nanoparticles for direct nose-to-brain delivery of drugs. Int J Pharm (2009) 1.36
Nasal drug delivery: new developments and strategies. Drug Discov Today (2002) 1.34
Development of neuropeptide drugs that cross the blood-brain barrier. NeuroRx (2005) 1.27
A strong neuroprotective effect of the autonomous C-terminal peptide of IGF-1 Ec (MGF) in brain ischemia. FASEB J (2005) 1.25
Is nose-to-brain transport of drugs in man a reality? J Pharm Pharmacol (2004) 1.25
Increasing volume of distribution to the brain with interstitial infusion: dose, rather than convection, might be the most important factor. Neurosurgery (1996) 1.19
Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice. Eur J Pharm Biopharm (2004) 1.18
Biodegradable mucoadhesive particulates for nasal and pulmonary antigen and DNA delivery. Adv Drug Deliv Rev (2005) 1.08
Nasal delivery of insulin using novel chitosan based formulations: a comparative study in two animal models between simple chitosan formulations and chitosan nanoparticles. Pharm Res (2002) 1.08
Intranasal delivery of HMGB1 siRNA confers target gene knockdown and robust neuroprotection in the postischemic brain. Mol Ther (2012) 1.05
Intranasal gene transfer by chitosan-DNA nanospheres protects BALB/c mice against acute respiratory syncytial virus infection. Hum Gene Ther (2002) 1.04
Biomedical and biotechnological applications of PEG- and PM-modified proteins. Trends Biotechnol (1995) 1.03
Mechano-growth factor reduces loss of cardiac function in acute myocardial infarction. Heart Lung Circ (2007) 1.01
Gene expression from recombinant viral vectors in the central nervous system after blood-brain barrier disruption. Neurosurgery (1995) 1.01
Nasal pH measurement: a reliable and repeatable parameter. Clin Otolaryngol Allied Sci (1999) 1.00
Influence of nano-carrier architecture on in vitro siRNA delivery performance and in vivo biodistribution: polyplexes vs micelleplexes. ACS Nano (2011) 0.98
Synthesis of TAT peptide-tagged PEGylated chitosan nanoparticles for siRNA delivery targeting neurodegenerative diseases. Biomaterials (2012) 0.97
Intranasal drug delivery. Adv Drug Deliv Rev (1998) 0.91
Thiolated chitosan nanoparticles enhance anti-inflammatory effects of intranasally delivered theophylline. Respir Res (2006) 0.87
Targeted brain delivery of 17 beta-estradiol via nasally administered water soluble prodrugs. AAPS PharmSciTech (2002) 0.87
Intranasal drug delivery of didanosine-loaded chitosan nanoparticles for brain targeting; an attractive route against infections caused by AIDS viruses. J Drug Target (2010) 0.86
The mucosal and systemic immune responses elicited by a chitosan-adjuvanted intranasal influenza H5N1 vaccine. Influenza Other Respir Viruses (2011) 0.85
Peptide derived from HIV-1 TAT protein destabilizes a monolayer of endothelial cells in an in vitro model of the blood-brain barrier and allows permeation of high molecular weight proteins. J Biol Chem (2012) 0.85
Intranasal delivery of siRNA to the olfactory bulbs of mice via the olfactory nerve pathway. Neurosci Lett (2012) 0.85
Chitosan-based hydrogels for nasal drug delivery: from inserts to nanoparticles. Expert Opin Drug Deliv (2010) 0.83
Targeting neurological disease with RNAi. Mol Biosyst (2007) 0.83
Ultrafine chitosan nanoparticles as an efficient nucleic acid delivery system targeting neuronal cells. Drug Dev Ind Pharm (2009) 0.83
Synthesis of thiolated chitosan and preparation nanoparticles with sodium alginate for ocular drug delivery. Mol Vis (2012) 0.82
Increased brain radioactivity by intranasal P-labeled siRNA dendriplexes within in situ-forming mucoadhesive gels. Int J Nanomedicine (2012) 0.82
Delivery of nerve growth factor to brain via intranasal administration and enhancement of brain uptake. J Pharm Sci (2009) 0.81
Preoperative hyperglycemia and complication risk following neurosurgical intervention: A study of 918 consecutive cases. Surg Neurol Int (2012) 0.81
Mechano-Growth Factor: an important cog or a loose screw in the repair machinery? Front Endocrinol (Lausanne) (2012) 0.80
Small interfering ribonucleic acid design strategies for effective targeting and gene silencing. Expert Opin Drug Discov (2011) 0.78
Permeation-enhancing effects of chitosan formulations on recombinant hirudin-2 by nasal delivery in vitro and in vivo. Acta Pharmacol Sin (2005) 0.76